Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 295,600 shares, an increase of 1,032.6% from the December 31st total of 26,100 shares. Based on an average daily trading volume, of 918,800 shares, the short-interest ratio is presently 0.3 days. Currently, 10.5% of the company’s shares are sold short.
Dermata Therapeutics Price Performance
Shares of DRMA remained flat at $0.46 on Thursday. 120,749 shares of the company were exchanged, compared to its average volume of 2,704,773. Dermata Therapeutics has a twelve month low of $0.37 and a twelve month high of $5.62. The stock’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.92.
Institutional Investors Weigh In On Dermata Therapeutics
Dermata Therapeutics Company Profile
Dermata Therapeutics, Inc, a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
- Five stocks we like better than Dermata Therapeutics
- Most active stocks: Dollar volume vs share volume
- 5 best fintech banks to invest in now
- What is the Hang Seng index?
- What are fintech companies?
- With Risk Tolerance, One Size Does Not Fit All
- Abbott Laboratories on track for new highs in 2024
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.